Recombinant CD40L (Ruplizumab Biosimilar) antibody

Catalog No. ABIN5564228

Product Details anti-CD40L (Ruplizumab Biosimilar) Antibody

Target: CD40L (Ruplizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human, Dog

Host: Human

Clonality: Monoclonal

Conjugate: This CD40L (Ruplizumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), Western Blotting (WB), Functional Studies (Func)

Specificity: Recognizes and binds human CD40L with an IC50 of 0.845 μg/mL.

Cross-Reactivity: Dog (Canine), Human

Cross-Reactivity (Details): Cross-reacts with canine CD40L.

Purity: >95 % (SDS-PAGE)

Endotoxin Level: <0.001EU/μg

Immunogen: Recombinant human CD40L.

Clone: Hu5c8

Isotype: IgG1

Application Details

Comment:

This antibody is a biosimilar called Ruplizumab (Antova, BG9588) and originally developed by Biogen. Ruplizumab is a CD40 ligand blocker designed for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis, but withdrawn from clinical trials due to side effects.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: In PBS.

Preservative: Without preservative

Storage: 4 °C,-20 °C

Storage Comment: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C. Stable for at least 3 months after receipt when stored at +4°C.

Expiry Date: 12 months

Target Details for CD40L (Ruplizumab Biosimilar)

Target: CD40L (Ruplizumab Biosimilar)

Abstract: CD40L (Ruplizumab Biosimilar) Products

Synonyms: CD154 antibody, CD40L antibody, HIGM1 antibody, IGM antibody, IMD3 antibody, T-BAM antibody, TNFSF5 antibody, TRAP antibody, gp39 antibody, hCD40L antibody, CD40 ligand antibody, CD40LG antibody

Target Type: Biosimilar

Background: CD40 Ligand (CD40L), renamed TNFSF5 but now also known as CD154, TRAP and gp39, is a 34-39 kDa type II transmembrane glycoprotein, that belongs to the TNF superfamily, and a surface receptor expressed on activated T cells which acts as a costimulatory molecule to trigger immune responses. CD40L binds to CD40, which is essential in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development and germinal center formation. CD40 is constitutively expressed by antigen presenting cells, including dendritic cells, B cells and macrophages. Consistent with its widespread expression on normal cells, CD40 is also expressed on a wide range of tumor cells. CD40L levels are increased in serum and in inflamed tissues of patients with autoimmune diseases.

UniProt: P29965